JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell NGXIRZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PjNGlvcGmkaYTpc44hd2ZiaIXtZY4hU1VvMUmtNVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl|MkO2JO69VQ>? NYPv[m5pW0GQR1XS
H4 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yNkewO{DPxE1? NUnTN21RW0GQR1XS
KGN cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmrvTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[yNFUh|ryP NHrOeWpUSU6JRWK=
786-0 cell NU\wRmk5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mo[3TY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|I6QDlizszN M2j0cXNCVkeHUh?=
769-P cell NF34VIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmruTY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFIzOjRizszN MmTrV2FPT0WU
K5 cell M1LMTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLyTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMEG2NlQh|ryP MnfhV2FPT0WU
MLMA cell M1vQVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnz0TY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA{OjF5IN88US=> NIDUNnlUSU6JRWK=
MLMA cell M{WzeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoLLTY5pcWKrdHnvckBw\iCqdX3hckBOVE2DIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yPFcxOyEQvF2= M1vXTXNCVkeHUh?=
EW-7 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmrtTY5pcWKrdHnvckBw\iCqdX3hckBGXy15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6zNlY6PSEQvF2= NHvHSopUSU6JRWK=
SW1088 cell NGT6elBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFA3PTFizszN NYDUOo51W0GQR1XS
MC-IXC cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFc4QTJizszN NF\FcplUSU6JRWK=
NCI-H2052 cell M{P4fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODhzNUeg{txO M4X3T3NCVkeHUh?=
IGR-1 cell M{TyV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHLn[3JKdmirYnn0bY9vKG:oIHj1cYFvKEmJUj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOjB{ODFOwG0> M3\TfHNCVkeHUh?=
DSH1 cell M1rFZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFvJTmlKdmirYnn0bY9vKG:oIHj1cYFvKESVSEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1Ojl4IN88US=> M{T4c3NCVkeHUh?=
PA-1 cell MlLLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3TQTmlvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuN|AxPToQvF2= M{\0SXNCVkeHUh?=
SK-MEL-3 cell M3n1Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWPtTldNUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwM{GyNFch|ryP MXnTRW5ITVJ?
SW900 cell NVTmR21HT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2PxOmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> Ml7oV2FPT0WU
CAKI-1 cell NG\hSXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXTJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI4OzhizszN NWLhXoFwW0GQR1XS
ES1 cell NXPFWVZXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUnvWZdzUW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzQDl5IN88US=> NXuzeWZ5W0GQR1XS
SK-N-DZ cell Mo\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;lN2hKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ{NUm1JO69VQ>? NYDQ[Yc2W0GQR1XS
RH-1 cell NFOyTZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnX6TY5pcWKrdHnvckBw\iCqdX3hckBTUC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62PFQ3OyEQvF2= Mn;jV2FPT0WU
ES8 cell NVrqZ4JFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWfJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkm3NFIh|ryP NHjlbndUSU6JRWK=
NEC8 cell NHnNeZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4mxdWlvcGmkaYTpc44hd2ZiaIXtZY4hVkWFODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|Y6QDJizszN M2HTRXNCVkeHUh?=
LNCaP-Clone-FGC cell NHXuWXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M37BU2lvcGmkaYTpc44hd2ZiaIXtZY4hVE6FYWCtR4xwdmVvRlfDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OzV|NjFOwG0> MnjTV2FPT0WU
HCE-4 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3zYSGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk5ODdizszN NGjvcFZUSU6JRWK=
U-118-MG cell MmDmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHnBNlJKdmirYnn0bY9vKG:oIHj1cYFvKFVvMUG4MW1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yMUC2OkDPxE1? MWrTRW5ITVJ?
GI-ME-N cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnTlTY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDd7NjFOwG0> MkLYV2FPT0WU
LB1047-RCC cell NELFV5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvVd5J7UW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOlE1OyEQvF2= MnjiV2FPT0WU
HT-1080 cell MmjlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUn2b|l5UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zOUmyNUDPxE1? MUXTRW5ITVJ?
NB69 cell NYm4W3k6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHwdGJKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM2ODR5IN88US=> MlnrV2FPT0WU
NCI-H1693 cell NFXQRopIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIiycWZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY6OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNES4PVUh|ryP M{jWUHNCVkeHUh?=
HSC-3 cell NUjTN3hTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI[zNZFKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41QTl|MzFOwG0> NVXaUYNnW0GQR1XS
MDA-MB-231 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\SPWJKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0zOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW1PFk6KM7:TR?= MWHTRW5ITVJ?
HOS cell NXz3U41{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{TTTGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63PFY{KM7:TR?= NV;NZZdRW0GQR1XS
BT-549 cell NYTRfG01T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnfnTY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QDdizszN NHjn[YRUSU6JRWK=
NB17 cell NWnUbG56T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4nnTWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|g6PzZizszN NGfBT5hUSU6JRWK=
5637 cell MnW0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3zNO2lvcGmkaYTpc44hd2ZiaIXtZY4hPTZ|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|k3PTJizszN MVPTRW5ITVJ?
OVCAR-8 cell NF20OHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3X5SGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTJ2M{[g{txO M1jKXXNCVkeHUh?=
G-402 cell NIXyWW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;2cndHUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTNyM{Wg{txO MljvV2FPT0WU
BB30-HNC cell NVyz[IZkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYn1bHl1UW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwMEeyNVgh|ryP NHfBUJBUSU6JRWK=
HCC1806 cell MoHUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXfoOpYyUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPFA3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yOEOzPUDPxE1? M3n6dnNCVkeHUh?=
COLO-800 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfRR3NKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5zMk[0JO69VQ>? MXjTRW5ITVJ?
FADU cell M4nTcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NU\3ZmVKUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PjV3NzFOwG0> NHrKOWFUSU6JRWK=
NCI-H1651 cell NVHzfGc5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4PvNWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5|OUSwPUDPxE1? NW[2OWtIW0GQR1XS
AGS cell NGPOXlZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEe3NVEh|ryP NX3NUpQzW0GQR1XS
CHP-212 cell M2HIZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGLzUHJKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? NIjzPZZUSU6JRWK=
YAPC cell NI\HbmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml3QTY5pcWKrdHnvckBw\iCqdX3hckB[SVCFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60O|cyOSEQvF2= M1v4SHNCVkeHUh?=
GOTO cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3uwdGlvcGmkaYTpc44hd2ZiaIXtZY4hT0:WTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFk2PzZizszN NVrVXVNJW0GQR1XS
KYSE-510 cell NVP1PFgxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH3MfWRKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOVExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53MUGg{txO MWnTRW5ITVJ?
NCI-H2342 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTN{N{ig{txO MWnTRW5ITVJ?
BFTC-905 cell MnnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDCUZJKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54MkizOUDPxE1? MVvTRW5ITVJ?
EW-16 cell NEO4PYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlrJTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxQTNizszN Mn2zV2FPT0WU
SK-MEL-30 cell NFzoN|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF3mbY5KdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{S1OFMh|ryP MWnTRW5ITVJ?
HLE cell NF;MdWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFLGW29KdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|c1QDlizszN MmXyV2FPT0WU
T98G cell MkHXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEn5ZXlKdmirYnn0bY9vKG:oIHj1cYFvKFR7OFegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6PjN3IN88US=> MmrIV2FPT0WU
HUTU-80 cell MkfOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFnreoFKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh2MkK4JO69VQ>? M33wPXNCVkeHUh?=
NOS-1 cell Ml7xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjuT29KdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PDd4NjFOwG0> M2fjZXNCVkeHUh?=
SW780 cell M2PKWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MljpTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVY6PDlizszN MmrDV2FPT0WU
KYSE-180 cell Ml:wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlXJTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTd4NUSg{txO MXzTRW5ITVJ?
MDA-MB-361 cell M{n5eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl6NkS3JO69VQ>? MmPmV2FPT0WU
SNU-C2B cell M{S3S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUKwS5FuUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtR|JDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5yMUGzPEDPxE1? MmSzV2FPT0WU
NCI-H661 cell NI\t[VVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4LDdmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB4OUSg{txO NGDQW4lUSU6JRWK=
OE33 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmK1TY5pcWKrdHnvckBw\iCqdX3hckBQTTN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6xOFM5QSEQvF2= NVrSXGZqW0GQR1XS
TYK-nu cell M2fMc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3vNTGlvcGmkaYTpc44hd2ZiaIXtZY4hXFmNLX71JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zOTh4MzFOwG0> M1LkcnNCVkeHUh?=
COLO-792 cell MlLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmPPTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOjV{MUmg{txO MoHNV2FPT0WU
HEL cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWTmS2JXUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlI3PzZizszN NY\ybVd6W0GQR1XS
D-566MG cell MkPuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml;qTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{OzR7MTFOwG0> MUjTRW5ITVJ?
U031 cell M1yxdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1fzTGlvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFE5OTZizszN Mm\BV2FPT0WU
COR-L23 cell NInKWG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ{OzR4IN88US=> MU\TRW5ITVJ?
NCI-H2452 cell NF3GZVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkS1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPTJ{OEGg{txO MVrTRW5ITVJ?
BB65-RCC cell NWe2fHF3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2Lle2lvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ2NUmg{txO M2\5eHNCVkeHUh?=
CAL-33 cell M{LI[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnnGTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PjZ3IN88US=> NWDOUI9nW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development, L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

p53 Signaling Pathway Map

Related p53 Products

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID